Published in Circ Res on June 11, 2004
Cardiac KATP channels in health and disease. J Mol Cell Cardiol (2005) 2.04
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. Br J Pharmacol (2006) 1.68
Nonsense mutations in hERG cause a decrease in mutant mRNA transcripts by nonsense-mediated mRNA decay in human long-QT syndrome. Circulation (2007) 1.43
Mechanisms of pharmacological rescue of trafficking-defective hERG mutant channels in human long QT syndrome. J Biol Chem (2005) 1.38
Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. J Clin Invest (2008) 1.18
Ether-a-go-go-related gene potassium channels: what's all the buzz about? Schizophr Bull (2007) 1.07
A highly conserved motif at the COOH terminus dictates endoplasmic reticulum exit and cell surface expression of NKCC2. J Biol Chem (2009) 1.04
Small GTPase determinants for the Golgi processing and plasmalemmal expression of human ether-a-go-go related (hERG) K+ channels. J Biol Chem (2008) 1.02
Alpha-actinin2 cytoskeletal protein is required for the functional membrane localization of a Ca2+-activated K+ channel (SK2 channel). Proc Natl Acad Sci U S A (2009) 1.01
Small GTPase Rab11b regulates degradation of surface membrane L-type Cav1.2 channels. Am J Physiol Cell Physiol (2011) 0.98
Food deprivation attenuates seizures through CaMKII and EAG K+ channels. PLoS Genet (2007) 0.95
Fever-triggered ventricular arrhythmias in Brugada syndrome and type 2 long-QT syndrome. Neth Heart J (2010) 0.94
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br J Pharmacol (2005) 0.94
Trafficking-deficient hERG K⁺ channels linked to long QT syndrome are regulated by a microtubule-dependent quality control compartment in the ER. Am J Physiol Cell Physiol (2011) 0.93
Robust L-type calcium current expression following heterozygous knockout of the Cav1.2 gene in adult mouse heart. J Physiol (2011) 0.92
Large-scale mutational analysis of Kv11.1 reveals molecular insights into type 2 long QT syndrome. Nat Commun (2014) 0.92
Rescue of protein expression defects may not be enough to abolish the pro-arrhythmic phenotype of long QT type 2 mutations. J Physiol (2016) 0.90
A splice site mutation in hERG leads to cryptic splicing in human long QT syndrome. J Mol Cell Cardiol (2008) 0.90
Combined hERG channel inhibition and disruption of trafficking in drug-induced long QT syndrome by fluoxetine: a case-study in cardiac safety pharmacology. Br J Pharmacol (2006) 0.89
Translational toxicology and rescue strategies of the hERG channel dysfunction: biochemical and molecular mechanistic aspects. Acta Pharmacol Sin (2014) 0.88
Nonsense-mediated mRNA decay caused by a frameshift mutation in a large kindred of type 2 long QT syndrome. Heart Rhythm (2011) 0.87
Conserved negative charges in the N-terminal tetramerization domain mediate efficient assembly of Kv2.1 and Kv2.1/Kv6.4 channels. J Biol Chem (2009) 0.87
Inhibition of HERG potassium channels by celecoxib and its mechanism. PLoS One (2011) 0.86
Activation of protein kinase C alters the intracellular distribution and mobility of cardiac Na+ channels. Am J Physiol Heart Circ Physiol (2011) 0.86
Properties of WT and mutant hERG K(+) channels expressed in neonatal mouse cardiomyocytes. Am J Physiol Heart Circ Physiol (2010) 0.86
KCNE Regulation of K(+) Channel Trafficking - a Sisyphean Task? Front Physiol (2012) 0.85
N-glycosylation-dependent control of functional expression of background potassium channels K2P3.1 and K2P9.1. J Biol Chem (2012) 0.84
Rescue of a trafficking defective human pacemaker channel via a novel mechanism: roles of Src, Fyn, and Yes tyrosine kinases. J Biol Chem (2009) 0.83
Wrecked regulation of intrinsically disordered proteins in diseases: pathogenicity of deregulated regulators. Front Mol Biosci (2014) 0.82
Mechanism of loss of Kv11.1 K+ current in mutant T421M-Kv11.1-expressing rat ventricular myocytes: interaction of trafficking and gating. Circulation (2012) 0.80
Role of the cytoplasmic N-terminal Cap and Per-Arnt-Sim (PAS) domain in trafficking and stabilization of Kv11.1 channels. J Biol Chem (2014) 0.80
Novel mechanisms of trafficking defect caused by KCNQ1 mutations found in long QT syndrome. J Biol Chem (2009) 0.80
Novel characteristics of a trafficking-defective G572R-hERG channel linked to hereditary long QT syndrome. Can J Cardiol (2010) 0.79
Using pharmacological chaperones to restore proteostasis. Pharmacol Res (2014) 0.79
Clinical observations of supraventricular arrhythmias in patients with brugada syndrome. Int J Clin Exp Med (2015) 0.78
Emerging concepts in the pharmacogenomics of arrhythmias: ion channel trafficking. Expert Rev Cardiovasc Ther (2010) 0.78
Class 3 inhibition of hERG K+ channel by caffeic acid phenethyl ester (CAPE) and curcumin. Pflugers Arch (2013) 0.78
Taxifolin Glycoside Blocks Human ether-a-go-go Related Gene K(+) Channels. Korean J Physiol Pharmacol (2013) 0.77
Partial restoration of the long QT syndrome associated KCNQ1 A341V mutant by the KCNE1 β-subunit. Biochim Biophys Acta (2011) 0.77
Neuronal and Cardiovascular Potassium Channels as Therapeutic Drug Targets: Promise and Pitfalls. J Biomol Screen (2015) 0.77
Blockade of permeation by potassium but normal gating of the G628S nonconducting hERG channel mutant. Biophys J (2011) 0.77
The role of heat shock proteins and co-chaperones in heart failure. Philos Trans R Soc Lond B Biol Sci (2018) 0.76
Mechanistic basis for type 2 long QT syndrome caused by KCNH2 mutations that disrupt conserved arginine residues in the voltage sensor. J Membr Biol (2013) 0.76
The use of Bcl-2 over-expression to stabilize hybridomas specific to the HERG potassium channel. J Immunol Methods (2011) 0.75
Intracellular Calcium Mobilization in Response to Ion Channel Regulators via a Calcium Induced Calcium Release Mechanism. J Pharmacol Exp Ther (2016) 0.75
Traffic jam at the sodium channel. Epilepsy Curr (2008) 0.75
Cardiovascular Action of Insulin in Health and Disease: Endothelial L-Arginine Transport and Cardiac Voltage-Dependent Potassium Channels. Front Physiol (2016) 0.75
The ever-shrinking world of cardiac ion channel remodeling: the role of microRNAs in heart disease. Heart Rhythm (2009) 0.75
RNA interference-based therapeutics for inherited long QT syndrome. Exp Ther Med (2015) 0.75
Pivotal Cytoprotective Mediators and Promising Therapeutic Strategies for Endothelial Progenitor Cell-Based Cardiovascular Regeneration. Stem Cells Int (2016) 0.75
Melatonin increases the regularity of cardiac rhythmicity in the Drosophila heart in both wild-type and strains bearing pathogenic mutations. J Comp Physiol B (2016) 0.75
Fatty acid analogue N-arachidonoyl taurine restores function of IKs channels with diverse long QT mutations. Elife (2016) 0.75
Total chemical synthesis and biophysical characterization of the minimal isoform of the KChIP2 potassium channel regulatory subunit. Protein Sci (2007) 0.75
Molecular pathogenesis of long QT syndrome type 2. J Arrhythm (2016) 0.75
Association of the hERG mutation with long‑QT syndrome type 2, syncope and epilepsy. Mol Med Rep (2016) 0.75
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol (2014) 9.96
Most LQT2 mutations reduce Kv11.1 (hERG) current by a class 2 (trafficking-deficient) mechanism. Circulation (2006) 3.23
High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. Am J Physiol Heart Circ Physiol (2011) 2.65
Genotype-phenotype aspects of type 2 long QT syndrome. J Am Coll Cardiol (2009) 2.65
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol (2011) 2.48
Molecular heterogeneity of calcium channel beta-subunits in canine and human heart: evidence for differential subcellular localization. Physiol Genomics (2004) 2.37
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2010) 1.87
Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 1.79
R231C mutation in KCNQ1 causes long QT syndrome type 1 and familial atrial fibrillation. Heart Rhythm (2010) 1.71
Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice. Am J Physiol Cell Physiol (2011) 1.69
Deranged sodium to sudden death. J Physiol (2015) 1.51
Pharmacological correction of long QT-linked mutations in KCNH2 (hERG) increases the trafficking of Kv11.1 channels stored in the transitional endoplasmic reticulum. Am J Physiol Cell Physiol (2013) 1.49
Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol (2004) 1.48
Blockade of HERG channels by HIV protease inhibitors. Lancet (2005) 1.44
Role of glycosylation in cell surface expression and stability of HERG potassium channels. Am J Physiol Heart Circ Physiol (2002) 1.38
A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. J Pharmacol Exp Ther (2012) 1.23
Fever-induced QTc prolongation and ventricular arrhythmias in individuals with type 2 congenital long QT syndrome. J Clin Invest (2008) 1.18
Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation (2002) 1.18
Thapsigargin selectively rescues the trafficking defective LQT2 channels G601S and F805C. J Biol Chem (2003) 1.16
Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone. Cardiovasc Res (2007) 1.15
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: I. Experimental analysis of the use-dependent block. Am J Physiol Heart Circ Physiol (2011) 1.08
Rate-dependent QT shortening mechanism for the LQT3 deltaKPQ mutant. Cardiovasc Res (2002) 1.07
The arrhythmogenic consequences of increasing late INa in the cardiomyocyte. Cardiovasc Res (2013) 1.03
Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart. Am J Physiol Heart Circ Physiol (2009) 1.03
Pharmacological rescue of trafficking defective HERG channels formed by coassembly of wild-type and long QT mutant N470D subunits. Am J Physiol Heart Circ Physiol (2004) 1.03
Small GTPase determinants for the Golgi processing and plasmalemmal expression of human ether-a-go-go related (hERG) K+ channels. J Biol Chem (2008) 1.02
Alpha1-syntrophin mutations identified in sudden infant death syndrome cause an increase in late cardiac sodium current. Circ Arrhythm Electrophysiol (2009) 1.02
Novel chemical suppressors of long QT syndrome identified by an in vivo functional screen. Circulation (2010) 1.01
Rescue of mutated cardiac ion channels in inherited arrhythmia syndromes. J Cardiovasc Pharmacol (2010) 1.00
Ranolazine selectively blocks persistent current evoked by epilepsy-associated Naν1.1 mutations. Br J Pharmacol (2010) 1.00
Kv11.1 (ERG1) K+ channels localize in cholesterol and sphingolipid enriched membranes and are modulated by membrane cholesterol. Channels (Austin) (2007) 0.99
Interaction with GM130 during HERG ion channel trafficking. Disruption by type 2 congenital long QT syndrome mutations. Human Ether-à-go-go-Related Gene. J Biol Chem (2002) 0.99
Small GTPase Rab11b regulates degradation of surface membrane L-type Cav1.2 channels. Am J Physiol Cell Physiol (2011) 0.98
Blockade of HERG cardiac K+ current by antifungal drug miconazole. Br J Pharmacol (2005) 0.98
An intronic mutation causes long QT syndrome. J Am Coll Cardiol (2004) 0.97
Microfluidic cell culture and its application in high-throughput drug screening: cardiotoxicity assay for hERG channels. J Biomol Screen (2010) 0.96
Mechanisms of atrial-selective block of Na⁺ channels by ranolazine: II. Insights from a mathematical model. Am J Physiol Heart Circ Physiol (2011) 0.94
Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br J Pharmacol (2005) 0.94
Simulation and mechanistic investigation of the arrhythmogenic role of the late sodium current in human heart failure. PLoS One (2012) 0.93
Specific serine proteases selectively damage KCNH2 (hERG1) potassium channels and I(Kr). Am J Physiol Heart Circ Physiol (2005) 0.93
The role of late I Na in development of cardiac arrhythmias. Handb Exp Pharmacol (2014) 0.93
Trafficking-deficient hERG K⁺ channels linked to long QT syndrome are regulated by a microtubule-dependent quality control compartment in the ER. Am J Physiol Cell Physiol (2011) 0.93
Intragenic suppression of trafficking-defective KCNH2 channels associated with long QT syndrome. Mol Pharmacol (2005) 0.91
Antiepileptic activity of preferential inhibitors of persistent sodium current. Epilepsia (2014) 0.91
Stem cells and their derivatives: a renaissance in cardiovascular translational research. J Cardiovasc Transl Res (2011) 0.89
Na+ channel function, regulation, structure, trafficking and sequestration. J Physiol (2015) 0.88
Properties of WT and mutant hERG K(+) channels expressed in neonatal mouse cardiomyocytes. Am J Physiol Heart Circ Physiol (2010) 0.86
Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat. Am J Physiol Heart Circ Physiol (2013) 0.85
The anti-malarial drug halofantrine and its metabolite N-desbutylhalofantrine block HERG potassium channels. Cardiovasc Res (2002) 0.84
The common African American polymorphism SCN5A-S1103Y interacts with mutation SCN5A-R680H to increase late Na current. Physiol Genomics (2011) 0.83
Ranolazine reduces neuronal excitability by interacting with inactivated states of brain sodium channels. Mol Pharmacol (2013) 0.83
Ranolazine block of human Na v 1.4 sodium channels and paramyotonia congenita mutants. Channels (Austin) (2011) 0.83
Is ranolazine an antiarrhythmic drug? Am J Physiol Heart Circ Physiol (2008) 0.82
A computational modelling approach combined with cellular electrophysiology data provides insights into the therapeutic benefit of targeting the late Na+ current. J Physiol (2015) 0.82
Effect of microculture on cell metabolism and biochemistry: do cells get stressed in microchannels? Anal Chem (2013) 0.81
Effect of ranolazine on ventricular repolarization in class III antiarrhythmic drug-treated rabbits. Heart Rhythm (2012) 0.81
Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol (2006) 0.81
In silico assessment of drug safety in human heart applied to late sodium current blockers. Channels (Austin) (2014) 0.81
Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine. Neuropharmacology (2012) 0.80
Mechanism of loss of Kv11.1 K+ current in mutant T421M-Kv11.1-expressing rat ventricular myocytes: interaction of trafficking and gating. Circulation (2012) 0.80
Selective inhibition of the late sodium current has no adverse effect on electrophysiological or contractile function of the normal heart. J Cardiovasc Pharmacol (2014) 0.80
Human embryonic stem cell-derived cardiomyocytes: drug discovery and safety pharmacology. Expert Opin Drug Discov (2007) 0.80
Carbon monoxide effects on human ventricle action potential assessed by mathematical simulations. Front Physiol (2013) 0.78
Molecular characterization, functional expression, and developmental profile of an ether à-go-go K+ channel in the tobacco hornworm Manduca sexta. J Neurobiol (2003) 0.78
Combined actions of ivabradine and ranolazine reduce ventricular rate during atrial fibrillation. J Cardiovasc Electrophysiol (2014) 0.77
Atrial Fibrillation and Long QT Syndrome Presenting in a 12-Year-Old Girl. Case Rep Pediatr (2012) 0.75
Potassium and long QT syndrome: a new look at an old therapy. J Am Coll Cardiol (2003) 0.75
Genetic basis for the origin of cardiac arrhythmias: implications for therapy. Curr Cardiol Rep (2002) 0.75
Purulent pericarditis induced by endobronchial needle injection of adenoviral-mediated gene therapy. Can J Cardiol (2003) 0.75
Harry A. Fozzard, MD: 1931–2014. Circ Res (2015) 0.75